Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Synergy Pharmaceuticals (SGYP -2.2%) slips after saying it has completed a Phase I clinical...

  • Friday, December 28, 2012, 1:33 PM ET
    Synergy Pharmaceuticals (SGYP -2.2%) slips after saying it has completed a Phase I clinical trials of SP-333, a treatment for ulcerative colitis and other GI diseases. According to the results, SP-333 exhibited potent anti-inflammatory activity in animal studies, which the company believes can provide a new way to treat UC patients with mild to moderate disease. The company plans to start a multi-dose escalation trial in January.
Track new comments on this story

This news story has 3 comments:

  •  
    Excellent Potential 1 st. qrtr. 2013 !!!!!! Long SGYP !!!!!
    28 Dec 2012, 01:49 PM Reply Like
  •  
    This sell on the news nonsense irritates me!
    28 Dec 2012, 03:11 PM Reply Like
  •  
    If the market overall was prospering so would have the stock. Be patient. SGYP will pay off.
    31 Dec 2012, 12:48 AM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »